Scipher Medicine
PrivateLast Round
PIPE
Jul 8, 2026
Est. Valuation
$180M
Total Funding Raised
$232.85M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Scipher Medicine operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series D Extension round in July 2024.
Scipher Medicine is a biotechnology company that provides a precision medicine platform to identify the most effective drug for patients with autoimmune diseases based on their unique biological profiles and molecular signature tests.
Sector
Healthcare & Life Sciences
Verticals
Precision Medicine, Biotechnology, Drug Discovery, Healthcare Analytics, Clinical Trials
Business Model
B2B
Customer Profile
Data as a Service, Services & Consulting, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Scipher Medicine Comparables
Compare Scipher Medicine with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IMIDomics | 78% | |
| Scailyte AG | 77% | |
| Immunai | 75% |
For institutional investors. Book with your work email.
Scipher Medicine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Jul 8, 2026 | ||||
| Series D Extension | Jul 30, 2024 | ||||
| Series D | Feb 24, 2022 | ||||
| Series C | Mar 24, 2021 | ||||
| Series B | Feb 19, 2020 | ||||
Series A | Sep 6, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Scipher Medicine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Granpool Innovative Investments | Series B, Seed |
| HV Fund | Series D |
| Kaiser Permanente Ventures | Series B |
| Khosla Ventures | Series B, Series C, PIPE, Series D, Series A |
| TD Securities | Series D |
| Blue Owl Capital | Series D |
| Neuberger Berman | PIPE, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors increased 70% MoM.
- Apr 29, 2025
Partnered with InnoSIGN Inc. to analyze immune-mediated diseases.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withNov 5, 2026
Scipher Medicine partners with Grupo Amarey to bring precision diagnostics to rheumatoid arthritis patients in Latin America, with the first PrismRA(R) patient tests completed in Colombia on Nov 5th '26.
- attends_eventOct 28, 2026
Scipher Medicine showcases its PrismTcell precision-diagnostics technology at ACR Convergence 2026, the annual American College of Rheumatology meeting in the United States.
- launchesOct 28, 2026
Scipher Medicine announces the expected launch of PrismTcell’s early physician access program, featuring a blood-based test designed to predict response to abatacept in patients with rheumatoid arthritis, in North Carolina on Oct 28th '26.
- attends_eventAug 31, 2026
Scipher Medicine attends the H.C. Wainwright Conference in New York and co-hosts 1x1 investor meetings on Sep 14th-16th '26.
For institutional investors. Book with your work email.
Scipher Medicine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Scipher Medicine's valuation, stock price, and market status.
Is Scipher Medicine a public or private company?
Scipher Medicine is a private company.
What is the current stock price of Scipher Medicine?
Scipher Medicine is a private company, so its shares have no public market price. Caplight tracks Scipher Medicine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Scipher Medicine worth (valuation)?
Scipher Medicine's valuation is estimated at $180.0M based on funding round data.
Can I buy Scipher Medicine stock?
Scipher Medicine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Scipher Medicine's last funding round?
Scipher Medicine's most recent funding round was PIPE on July 8, 2026.
Who are the main investors in Scipher Medicine?
Key investors in Scipher Medicine include Khosla Ventures, TD Securities, Blue Owl Capital, Northpond Ventures, Optum Ventures.
Will Scipher Medicine IPO soon?
No public IPO plans have been announced for Scipher Medicine.
How can I track Scipher Medicine secondary market activity?
Caplight tracks bids, offers, and trades in Scipher Medicine's shares on secondary markets.